Approval of Ribasphere 200mg for treatment of chronic hepatitis C
Approval of Ribasphere 200mg for treatment of chronic hepatitis C
CRANBERRY TOWNSHIP, PA., April 07, 2004 -- Three Rivers
Pharmaceuticals announced that the FDA has granted marketing
approval for its Ribasphere (ribavirin capsules) 200mg in
combination with interferon alfa-2b for the treatment of Hepatitis
C (HCV).
President and CEO Donald J. Kerrish, RPh. stated: "The approval of
Ribasphere marks a milestone in the treatment of HCV. Ribasphere is
positioned to break down the economic barriers that have existed
for the past decade in treating this chronic and potentially deadly
disease." Traditionally the cost of treatment for HCV can range
from $20,000 - $25,000 annually. "Our aim is to bring affordable
medicine to all individuals infected with this dreadful
disease."
Hepatitis C affects nearly 4 million Americans and 170 million people worldwide. HCV is responsible for 8,000 to 10,000 deaths per year in the United States and is the number one cause of liver transplants. HCV can also lead to cirrhosis, end-stage liver disease, and liver cancer. Over 30,000 new cases are diagnosed each year.
Source: Three Rivers Pharmaceuticals www.3riverspharma.com
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec





